ATE475883T1 - Verfahren zur messung der wirkstärke von glatirameracetat - Google Patents

Verfahren zur messung der wirkstärke von glatirameracetat

Info

Publication number
ATE475883T1
ATE475883T1 AT02790028T AT02790028T ATE475883T1 AT E475883 T1 ATE475883 T1 AT E475883T1 AT 02790028 T AT02790028 T AT 02790028T AT 02790028 T AT02790028 T AT 02790028T AT E475883 T1 ATE475883 T1 AT E475883T1
Authority
AT
Austria
Prior art keywords
glatiramer acetate
measuring
power
provides
subject invention
Prior art date
Application number
AT02790028T
Other languages
English (en)
Inventor
Ety Klinger
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23326090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE475883(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE475883T1 publication Critical patent/ATE475883T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5428—IL-10
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/55—IL-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02790028T 2001-12-04 2002-12-04 Verfahren zur messung der wirkstärke von glatirameracetat ATE475883T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33876701P 2001-12-04 2001-12-04
PCT/US2002/038859 WO2003048735A2 (en) 2001-12-04 2002-12-04 Processes for the measurement of the potency of glatiramer acetate

Publications (1)

Publication Number Publication Date
ATE475883T1 true ATE475883T1 (de) 2010-08-15

Family

ID=23326090

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02790028T ATE475883T1 (de) 2001-12-04 2002-12-04 Verfahren zur messung der wirkstärke von glatirameracetat

Country Status (21)

Country Link
US (6) US7429374B2 (de)
EP (1) EP1459065B1 (de)
JP (1) JP4369234B2 (de)
KR (1) KR100657048B1 (de)
CN (1) CN1308683C (de)
AT (1) ATE475883T1 (de)
AU (1) AU2002353059B2 (de)
CA (1) CA2469393C (de)
CY (1) CY1110878T1 (de)
DE (1) DE60237170D1 (de)
DK (1) DK1459065T3 (de)
ES (1) ES2349033T3 (de)
IL (3) IL162127A0 (de)
IS (1) IS7286A (de)
MX (1) MXPA04005433A (de)
NO (1) NO338247B1 (de)
NZ (1) NZ533327A (de)
PT (1) PT1459065E (de)
SI (1) SI1459065T1 (de)
WO (1) WO2003048735A2 (de)
ZA (1) ZA200404472B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
IL141021A0 (en) 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
US7429374B2 (en) 2001-12-04 2008-09-30 Teva Pharmaceutical Industries, Ltd. Process for the measurement of the potency of glatiramer acetate
EP1778286A4 (de) * 2004-03-03 2009-04-08 Teva Pharma Kombinationstherapie mit glatiramer-acetat und riluzol
ZA200702591B (en) * 2004-09-09 2009-03-25 Teva Pharma Process for preparation of mixtures of polypeptides using purified hydrobromic acid
HRP20160455T1 (hr) * 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
US8324641B2 (en) * 2007-06-29 2012-12-04 Ledengin, Inc. Matrix material including an embedded dispersion of beads for a light-emitting device
ES2541780T3 (es) * 2004-11-29 2015-07-24 Yeda Research And Development Co., Ltd. Inducción de la neurogénesis y terapia con células madre en combinación con el Copolímero 1
JP2008528589A (ja) * 2005-02-02 2008-07-31 テバ ファーマシューティカル インダストリーズ リミティド 水素化分解を用いてポリペプチド混合物を作成する方法
WO2006089164A1 (en) * 2005-02-17 2006-08-24 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
CA2606194A1 (en) * 2005-04-25 2006-11-02 Yeda Research And Development Company Markers associated with the therapeutic efficacy of glatiramer acetate
US8753833B2 (en) 2007-06-21 2014-06-17 Momenta Pharmaceuticals, Inc. Copolymer assay
CA2702437C (en) * 2007-11-28 2013-06-25 Teva Pharmaceutical Industries Ltd. Method of delaying the onset of clinically definite multiple sclerosis
ES2449865T5 (es) 2008-04-16 2022-11-18 Momenta Pharmaceuticals Inc Análisis de composiciones de copolímeros de aminoácidos
NZ598661A (en) 2009-08-20 2013-02-22 Yeda Res & Dev Low frequency glatiramer acetate therapy
EP2526420A4 (de) * 2009-11-17 2013-09-18 Ares Trading Sa Verfahren zur verbesserung der gestalt, bioverfügbarkeit und effizienz von zufälligen sequenzpolymerzusammensetzungen mit serumproteinbasiertem nachweis von zufälligen sequenzpolymerzusammensetzungen
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
CA2814500A1 (en) 2010-10-11 2012-04-19 Teva Pharmaceutical Industries Ltd Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
HK1200274A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
US20130210054A1 (en) * 2012-02-09 2013-08-15 Momenta Pharmaceuticals, Inc. Amino Acid Copolymer Assay
EP2642290A1 (de) 2012-03-19 2013-09-25 Synthon BV Potenztest basierend auf der humanen Glatiramer-Acetatmonzytzelllinie
WO2013139728A1 (en) 2012-03-19 2013-09-26 Synthon Bv Glatiramer acetate human monocyte cell-based potency assay
HK1213830A1 (zh) 2012-10-10 2016-07-15 Teva Pharmaceutical Industries Ltd. 用於预测醋酸格拉替雷临床反应的生物标志物
MX2015008754A (es) * 2013-01-04 2016-04-11 Teva Pharma Caracterizacion de un medicamento relacionado con acetato de glatiramer.
CN105377308B (zh) * 2013-03-14 2019-07-26 迈兰公司 醋酸格拉替雷响应生物标志物mRNA效力测定
WO2014173463A1 (en) * 2013-04-26 2014-10-30 Synthon Bv Glatiramer acetate human monocytic cell line-based potency assay
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US9995734B2 (en) 2013-10-24 2018-06-12 Mylan Inc. Human T cell line assay for evaluating the immunologic identity of glatiramer acetate preparations
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
WO2016128957A1 (en) * 2015-02-12 2016-08-18 Insight Biopharmaceuticals Ltd. Methods of determining relative potency of glatiramer acetate and use thereof in preparing a batch of glatiramer acetate as acceptable for pharmaceutical use
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
EP4255989A2 (de) 2020-12-03 2023-10-11 Beckman Coulter, Inc. Zusammensetzungen und verfahren für stabile trypanblau-lösungen

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US3991210A (en) 1974-03-11 1976-11-09 The Dow Chemical Company Acetamidine urinary antiseptics
US4129666A (en) 1977-04-29 1978-12-12 Walter Wizerkaniuk Method of providing pellets with a water insoluble coating using a melt
US4339431A (en) 1980-12-31 1982-07-13 Colgate-Palmolive Company Anticalculus oral composition
JPS6053535A (ja) 1983-09-02 1985-03-27 Nitto Boseki Co Ltd 規則性ポリアミノ酸樹脂の製造方法
SU1182051A1 (ru) 1984-04-28 1985-09-30 Таджикский государственный университет им.В.И.Ленина Политрипептиды,обладающие энантовой селективностью в реакци х гидролиза @ -нитрофениловых эфиров карбобензокси - @ - и @ -аланина
DE3684333D1 (de) 1985-06-18 1992-04-16 Univ Emory Biologisch wirksame kopolymere.
DD257174A3 (de) 1985-12-20 1988-06-08 Ve Forschungszentrum Biotechno Verfahren zur herstellung der peptide z-ala-ala-lon-p-nitranilid oder z-asp-phe-ome mit metalloprotease
SU1469826A1 (ru) 1986-05-30 1995-11-20 Институт Высокомолекулярных Соединений Ан Ссср Сополимер l-лизина с l-глутаминовой кислотой, содержащий дофаминовые боковые группы, обладающий пролонгированной гипотензивной активностью и компенсаторным эффектом при геморрагическом шоке, и способ его получения
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
EP0359783B2 (de) 1987-06-24 2002-04-17 Autoimmune, Inc. Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen
CA2009996A1 (en) 1989-02-17 1990-08-17 Kathleen S. Cook Process for making genes encoding random polymers of amino acids
SU1690368A1 (ru) 1989-07-20 1995-08-20 Институт Высокомолекулярных Соединений Ан Ссср Статистические сополимеры в качестве низкотоксичных веществ, обладающих пролонгированным гипотензивным действием, и способ их получения
DE3930733A1 (de) 1989-09-14 1991-03-28 Roehm Gmbh Verfahren zur herstellung eines komplexierten arzneimittels
FR2658076B1 (fr) 1990-02-12 1992-06-12 Sanofi Sa Composition cosmetique contenant des copolymeres d'aminoacides, utile comme agent hydratant.
AU8305491A (en) 1990-08-01 1992-03-02 Cytel Corporation Novel immunosuppressant peptides
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5734023A (en) 1991-11-19 1998-03-31 Anergen Inc. MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
US5583031A (en) 1992-02-06 1996-12-10 President And Fellows Of Harvard College Empty major histocompatibility class II heterodimers
AU664112B2 (en) 1992-07-31 1995-11-02 Merrell Dow Pharmaceuticals Inc. Synthetic peptide lung surfactants having covalently bonded antioxidants
AU6916694A (en) 1993-05-19 1994-12-12 Cytel Corporation Novel treatments for allergic diseases
CN1504462A (zh) 1994-03-31 2004-06-16 ������˹ҩƷ��˾ 作为白细胞介素抑制剂的嘧啶基衍生物
CA2186873A1 (en) 1994-04-01 1995-10-12 Charles J. Hackett Haptenated peptides and uses thereof
US5591629A (en) 1994-04-29 1997-01-07 Mayo Foundation For Medical Education & Research Monoclonal antibodies which promote central nervous system remyelination
US5502022A (en) 1994-05-16 1996-03-26 Biosepra, Inc. Chromatography adsorbents utilizing mercapto heterocyclic ligands
WO1995031997A1 (en) 1994-05-20 1995-11-30 UNITED STATES OF AMERICA, represented by THE SECRETARY OF THE ARMY Model for testing immunogenicity of peptides
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
GB9411292D0 (en) 1994-06-06 1994-07-27 Teva Pharma Pharmaceuticals compositions
US5858964A (en) 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
US5665764A (en) 1995-06-02 1997-09-09 Warner-Lambert Company Tricyclic inhibitors of matrix metalloproteinases
US5627206A (en) 1995-06-02 1997-05-06 Warner-Lambert Company Tricyclic inhibitor of matrix metalloproteinases
US5719296A (en) 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
DE69718968T2 (de) 1996-01-17 2003-10-09 Taiho Pharmaceutical Co. Ltd., Tokio/Tokyo 3-(bis-substituierte-phenylmethylen)oxindol-derivate
US5716946A (en) 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
IL119989A0 (en) 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6114317A (en) 1998-05-21 2000-09-05 Wisconsin Alumni Research Foundation Method of locking 1α-OH of vitamin D compounds in axial orientation
IL141021A0 (en) 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
WO2000005249A2 (en) 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
DK2239269T3 (da) 1998-09-25 2013-04-29 Yeda Res & Dev Anvendelse af peptider afledt af copolymer-1 som molekylvægtsmarkører
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2000020010A1 (en) 1998-10-02 2000-04-13 Yeda Research And Development Co., Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
AU775073C (en) 1998-11-12 2007-05-03 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD
JP4328050B2 (ja) 2000-01-20 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
IL150895A0 (en) 2000-02-18 2003-02-12 Teva Pharma Oral, nasal and pulmonary formulations of copolymer-1
IL152738A0 (en) 2000-05-10 2003-06-24 Mayo Foundation Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
US20020107388A1 (en) 2000-05-12 2002-08-08 Vandenbark Arthur A. Methods of identifying and monitoring disease-associated T cells
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
HUP0302333A3 (en) 2000-06-05 2005-07-28 Teva Pharma The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders
EP1294390B1 (de) 2000-06-07 2006-01-04 YEDA RESEARCH AND DEVELOPMENT CO., Ltd. Verwendung des copolymer-1 peptids sowie von damit verwandten peptiden und polypeptiden und von damit behandelten t-zellen zur neuroprotektion vor glutamattoxizitaet
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
CN2469393Y (zh) 2001-03-08 2002-01-02 祁新 暖气热水器
CN1152258C (zh) * 2001-03-19 2004-06-02 上海肿瘤特殊项目检测中心 一种检测化学药物在体内抗癌功效的方法
EP1407294A4 (de) 2001-06-07 2007-05-30 Univ Kentucky Res Found Nanoscintillationssysteme zum wassergestützten flüssigscintillationszählen
US7429374B2 (en) 2001-12-04 2008-09-30 Teva Pharmaceutical Industries, Ltd. Process for the measurement of the potency of glatiramer acetate
WO2004043995A2 (en) 2002-11-13 2004-05-27 Apotex Pharmachem Inc. Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
RU2339397C2 (ru) * 2003-01-21 2008-11-27 Йеда Рисерч Энд Дивелопмент Ко.Лтд. Сор1 для лечения воспалительных заболеваний кишечника
WO2004103297A2 (en) * 2003-05-14 2004-12-02 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
EP1678315B1 (de) * 2003-09-19 2011-08-03 Sangamo BioSciences, Inc. Gentechnisch hergestellte zinkfingerproteine zur regulation der genexpression
JP2007509981A (ja) 2003-10-31 2007-04-19 テバ ファーマシューティカル インダストリーズ リミティド 薬物デリバリー用ナノ粒子
HRP20160455T1 (hr) 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
ZA200702591B (en) * 2004-09-09 2009-03-25 Teva Pharma Process for preparation of mixtures of polypeptides using purified hydrobromic acid
AR052321A1 (es) 2004-10-29 2007-03-14 Sandoz Ag Procesos para la preparacion de un polipeptido
JP2008528589A (ja) 2005-02-02 2008-07-31 テバ ファーマシューティカル インダストリーズ リミティド 水素化分解を用いてポリペプチド混合物を作成する方法
CA2606194A1 (en) * 2005-04-25 2006-11-02 Yeda Research And Development Company Markers associated with the therapeutic efficacy of glatiramer acetate
US20070059798A1 (en) * 2005-09-09 2007-03-15 Alexander Gad Polypeptides useful for molecular weight determinations
JP2009542864A (ja) 2006-07-05 2009-12-03 モメンタ ファーマシューティカルズ インコーポレイテッド コポリマー１の調製のための改良法
ITRM20070552A1 (it) 2007-10-23 2009-04-24 Acqua Minerale S Benedetto S P Contenitore in materiale plastico

Also Published As

Publication number Publication date
SI1459065T1 (sl) 2010-11-30
AU2002353059B2 (en) 2008-06-19
AU2002353059A1 (en) 2003-06-17
WO2003048735A3 (en) 2003-09-18
EP1459065A4 (de) 2008-08-27
HK1070421A1 (en) 2005-06-17
IL162127A0 (en) 2005-11-20
CA2469393C (en) 2010-05-25
WO2003048735A2 (en) 2003-06-12
US7429374B2 (en) 2008-09-30
CN1308683C (zh) 2007-04-04
ES2349033T3 (es) 2010-12-22
ZA200404472B (en) 2005-11-30
NO20042816L (no) 2004-09-06
KR20050044676A (ko) 2005-05-12
DK1459065T3 (da) 2010-10-11
DE60237170D1 (de) 2010-09-09
JP4369234B2 (ja) 2009-11-18
MXPA04005433A (es) 2004-10-11
CA2469393A1 (en) 2003-06-12
CN1618018A (zh) 2005-05-18
EP1459065B1 (de) 2010-07-28
EP1459065A2 (de) 2004-09-22
NO338247B1 (no) 2016-08-08
US7923215B2 (en) 2011-04-12
US20150094488A1 (en) 2015-04-02
US20110189706A1 (en) 2011-08-04
JP2005511060A (ja) 2005-04-28
US20160025707A1 (en) 2016-01-28
KR100657048B1 (ko) 2006-12-12
IL198285A (en) 2013-07-31
PT1459065E (pt) 2010-10-11
US20090053253A1 (en) 2009-02-26
IL198285A0 (en) 2011-07-31
IL162127A (en) 2010-11-30
NZ533327A (en) 2006-11-30
CY1110878T1 (el) 2015-06-10
IS7286A (is) 2004-05-26
US20120309671A1 (en) 2012-12-06
US8389228B2 (en) 2013-03-05
US20030170729A1 (en) 2003-09-11

Similar Documents

Publication Publication Date Title
ATE475883T1 (de) Verfahren zur messung der wirkstärke von glatirameracetat
DE50303749D1 (de) Verfahren zur herstellung von phthalocyaninpigmentzubereitungen
DE50015623D1 (de) Kovalent verbrückte insulindimere
MXPA03006093A (es) Derivados de n(fenilsulfonil)glicina y su uso terapeutico.
DE60215476D1 (de) Vorrichtung zur prüfung der auflösung von produkten
DE60234952D1 (de) VERFAHREN ZUR HERSTELLUNG VON HEXAHYDROFUROc2,3-BÜFURAN-3-OL
DE602004017731D1 (de) Verfahren zur herstellung von 1-ä(benzimidazol-1-yl)chinolin-8-ylüpiperidin-4-ylaminderivaten
DE60124482D1 (de) Verfahren zur Herstellung von Xylylendiamin
DE69938935D1 (de) Zyklische conotoxin-peptide
DE69924846D1 (de) Thyroidhormon-analoga und verfahren zu ihrer herstellung
DE19983660T1 (de) Verfahren zur Aufreinigung von Lösungsmitteln, die bei der Herstellung von pharmazeutischen Zusammensetzungen nützlich sind
DE602004014805D1 (de) Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten
DE60323793D1 (de) Verfahren zur Herstellung von Fluorhalogenethern
DE10290269T1 (de) Verfahren zur Herstellung von Zyklischem Formal
DE60233589D1 (de) Verfahren zur herstellung von echinocandinderivaten
DE60210778D1 (de) Verfahren zur herstellung von 4-amino-2,5-bisheterocyclylchinazolinen
ATE254137T1 (de) ßLIGAND PRESENTING ASSEMBLYß (LPA), VERFAHREN ZU DESSEN HERSTELLUNG UND VERWENDUNGEN
DE60209011D1 (de) Verfahren zur herstellung von 7-substituierten 3-alkyl-3h-isobenzofuran-1-onderivaten
DE60300201D1 (de) Verfahren zur Herstellung von Polyetherpolyolen
ATE250578T1 (de) Indenoindolon-derivate, verfahren zu ihrer herstellung und die enthaltenden pharmazeutischen zusammensetzungen
DE602004031727D1 (de) Neues verfahren und zwischenprodukte zur herstellung von 19-nor-steroiden
DE60236303D1 (de) Verfahren zur herstellung von 14-beta-hydroxybaccatin-iii-1,14-carbonat
ATE537160T1 (de) Verfahren zur herstellung von 14beta- hydroxybaccatin-iii-1,14-carbonat
DE60108515D1 (de) Verfahren zur herstellung eines pgd2-antagonisten
DE50203367D1 (de) Verfahren zur herstellung von orthocarbonsäuretrialkylestern

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1459065

Country of ref document: EP